Subscribe to Newsletter
Subspecialties Retina, Retina

Same Difference

In the fight against neovascular age-related macular degeneration (AMD), there are three heavyweights in the arena: ranibizumab, aflibercept, and bevacizumab. Although bevacizumab is commonly used off-label, ranibizumab and aflibercept are both indicated for the treatment of neovascular AMD. But which to choose?

It’s known that all three are roughly similar in terms of efficacy and safety – aflibercept’s approval was based on the Phase III VIEW trials which found that it was non-inferior to ranibizumab (1),(2), and the CATT trial showed comparable outcomes with both ranibizumab and bevacizumab (3). But we also know that the real-world outcomes of patients receiving ranibizumab for the treatment of neovascular AMD don’t match those in the clinical trials (4). So across all of the “heavyweights,” is there a best choice amongst them in the real world?

Figure 1. Summary of key results from the observational study after patients received 12 months of treatment with ranibizumab or aflibercept. A total of 394 eyes from 372 patients were followed between December 1, 2013 and January 31, 2015. CNV, choroidal neovascular membrane (5).

To address this question, a multinational team mined the Fight Retinal Blindness registry to directly compare outcomes of patients treated with ranibizumab versus those treated with aflibercept (5). What they found was that patients’ outcomes were similar after 12 months of treatment, irrespective of the drug used: there were no significant differences in visual acuity (VA) improvement nor frequency of treatment between eyes treated with either drug (Figure 1). They also found that more patients switched from ranibizumab to aflibercept than aflibercept to ranibizumab (13.7 percent vs. 3 percent, respectively), but that there was no VA benefit associated with the switch.

Concluding that both drugs “delivered similar, good outcomes in routine clinical practice,” the authors acknowledge that “a randomized controlled trial would be required to demonstrate the superiority of one drug formally; however, numbers would be prohibitively large based on event estimates from this study.”

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. U Schmidt-Erfurth et al.,“Intravitreal aflibercept injection for newovascular age-related macular degeneration: ninety-six-week results of the VIEW studies”, Ophthalmol, 121, 193–201 (2014). PMID: 24084500.
  2. JS Heier et al., “Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration”, Ophthalmol, 119, 2537–2548 (2012). PMID: 23084240.
  3. DF Martin et al., “Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results”, Ophthalmol, 119, 1388–1398 (2012). PMID: 22555112.
  4. FG Holz et al., “Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration”, Br J Ophthalmol, 99, 220–226 (2014). PMID: 25193672.
  5. MC Gillies et al., “Twelve month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study”, Ophthalmol, 123, 2545–2553 (2016). PMID: 27707549.
About the Author
Ruth Steer
Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: